New draft guideline is out for consultation until 6 August and consolidates eight previous guidelines on smoking cessation.

NICE has recommended the use of secukinumab as an option for treating a chronic back pain condition affecting young adults.

Multiple sclerosis charities have expressed their disappointment at NICE’s decision not to recommend ozanimod for patients in England and Wales. 

NICE is promising to speed up patients' access to the latest and most effective treatments as part of its new five-year strategy.

People with chronic primary pain should be offered a range of treatments to help them manage their condition, says NICE in a new guideline.

PLASMA offers lower risk of serious complications, and shorter hospital stay and cost savings to NHS.

Local health commissioners should consider promoting community pharmacies as a first port of call for health and wellbeing, NICE has said. 

Several commonly used treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE says in new draft guidance.

Rezum recommended as a treatment option for moderate to severe lower urinary tract symptoms.

The Commission on Human Medicines has said patients can take paracetamol or ibuprofen when self-medicating for symptoms of Covid-19.

Fremanezumab now available on the NHS in England and Wales for up to 10,000 people.

Digital tools should be offered in addition to existing health services, not as a replacement, says NICE

NICE is calling for the NHS to make greater use of community pharmacies to promote health and wellbeing in local areas.

Doctors can prescribe Epidyolex with clobazam, a seizure-preventing cannabis-based treatment.

PHE is collaborating with the Scottish, Welsh and Northern Ireland governments to produce the first UK-wide clinical guidelines for alcohol misuse.

European authorities have for the first time approved a cannabis-based medicine for use in severe childhood epilepsy.

A handheld device that delivers a small electric current has been recommended in draft guidance by NICE.

The new recommendations reduce the CVD risk threshold at which treatment for hypertension should be considered.

Sir Andrew Dillon has announced his intention to stand down as chief executive at the National Institute for Health and Care Excellence (NICE).